Pancreatic Cancer Clinical Trial
Official title:
A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
Status | Recruiting |
Enrollment | 15 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Histologically and/or cytologically proven locally advanced or metastatic pancreatic adenocarcinoma - Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery or the patient does not wish to go through surgery - Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician - Interstitial radiation indication validated by a multidisciplinary team - Measurable lesion per RECIST (version 1.1) criteria - Lesion size = 5 cm in the longest diameter - Age =18 years old - ECOG Performance Status Scale = 2 - Life expectancy is more than 6 months - WBC = 3500/µl, granulocyte = 1500/µl - Platelet count =60,000/µl - Calculated or measured creatinine clearance = 60cc/min. Calculated or measured creatinine clearance can be= 40cc/min given stability of creatinine levels over the past three weeks (at least 1 test per week). - AST and ALT = 2.5 X upper limit of normal (ULN) - INR < 1.4 for patients not on Warfarin - Subjects are willing and able to sign an informed consent form - Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy. - Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. Exclusion Criteria: - Concomitant chemotherapy or immunotherapy within the past 4 weeks - Brain metastases - Borderline unresectable pancreatic cancer, and/or cases fit for surgical exploration unless patient refuses surgery - Known hypersensitivity to any of the components of the treatment. - Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids. - Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. - Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints. - Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. - Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT. - Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. - Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT. - High probability of protocol non-compliance (in opinion of investigator). - Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT. |
Country | Name | City | State |
---|---|---|---|
Israel | Wolfson Medical Center | H_olon | |
Israel | Hadassah Ein Kerem | Jerusalem |
Lead Sponsor | Collaborator |
---|---|
Alpha Tau Medical LTD. |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory objective-Blood samples will be collected for immune response biomarker analyses. Blood samples will be analyzed using FACS and change to the following immune biomarkers will be assessed: CD3, CD4, CD8, CD69, CD137 | • Changes in immune markers following treatment with the Alpha DaRT seeds for the treatment of advanced pancreatic cancer. o CD3
CD4 CD8 CD69 CD137 |
1 month | |
Other | Exploratory objective | Tumor response using EUS | 1&3 months | |
Other | Blood radioactivity measurements | Exploratory Objective-Blood samples will be collected and shipped using a designated sample collection kit provided by the Sponsor. The vials will be sent to a central vendor per the instruction provided in the associated laboratory manual. | week 0 and week 7, 1 and 2 months | |
Other | Urine radioactivity measurements | Urine samples will be collected and shipped using a designated sample collection kit provided by the Sponsor . the vials will be sent to central vendor per the instruction provided in the associated laboratory manual | week 0 and week 7, 1 and 2 months | |
Primary | Feasibility - DaRT seed placement | Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging | From Day 0 | |
Primary | Safety - Adverse events | Safety will be determined according to the overall incidence of device related SAE's graded according to CTCAE v5.0 criteria | up to 3 months | |
Secondary | Efficacy -Alpha DaRT seeds | The secondary objective of the study is to evaluate the efficacy of the Alpha DaRT seeds for advanced pancreatic cancer patients with respect to quality of life and tumor size. | 1 month and 3 months] | |
Secondary | Efficacy-Alpha DaRT seeds | Change in CA19-9 levels | 1 month and 3 months | |
Secondary | Efficacy-Alpha DaRT seeds | Tumor Coverage | immediately following the insertion procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|